Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EMD Millipore Launches New Kits for Use on Gyros’ Immunoassay Platform

Published: Wednesday, March 26, 2014
Last Updated: Tuesday, March 25, 2014
Bookmark and Share
Ready-to-use kits are fully qualified for reliable use in clinical research.

Gyros AB has announced that EMD Millipore, Life Science division of Merck KGaA of Darmstadt, Germany, has released five new immunoassay kits designed specifically for use on Gyrolab™ xP workstation.

The new, fully qualified GyroMark™ HT kits from EMD Millipore will enable clinical researchers and drug developers to generate valuable research data much faster than typical ELISA kits.

Traditional ELISAs can consume significant time, sample and reagents. With the fully automated, walk-away system from Gyros, up to 480 data points can be generated in a run.

“We are very pleased to be able to partner with Gyros to fill a commercial need to provide immunoassay kits requiring only nanoliter sample volume on a truly high-throughput platform,” said Jehangir Mistry, PhD, General Manager, Multiplex & Immunoassays at EMD Millipore.

The initial launch includes five assays for important metabolic and toxicity biomarkers, such as GLP-1, Insulin, Clusterin and KIM-1.

EMD Millipore plans to release additional kits this year and is offering custom kits for companies who have specific needs or unique or novel antibodies.

Because the Gyrolab platform employs microfluidic technology with parallel processing, it offers many advantages over traditional assays in addition to reagent and time savings. GyroMark HT assays provide:

• accuracy over a four-log dynamic range (compared to two logs for ELISAs)
• elimination of cross-talk and plate position artifacts
• simplified sample prep (only 1:2 dilution necessary) with reduced matrix interference

Gyros’ Global Marketing Director Maria Hjortsmark commented: “Gyrolab system revolutionizes immunoassays, enabling scientists to analyze large numbers of samples in parallel, at nanoliter scale and using a fully automated system. We are delighted that EMD Millipore has now chosen to work with us to develop off-the-shelf kits, to further reduce time to results, freeing up analyst time and offering an easier route to robust, reproducible data.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Gyros Immunoassay Platform Selected by BioAgilytix Labs to Support Bioanalysis Services
Gyros AB announced that BioAgilytix Labs has invested in two Gyrolab™ xP workstations to support its bioanalysis services.
Tuesday, November 12, 2013
Gyros AB Appoints Dr. Claus Braestrup to the Board of Directors
Dr. Braestrup is a member of the Board of Directors of Bavarian Nordic A/S, Chairman of the Board of Probiodrug AG and a member of the Boards of Santaris Pharma A/S and Evolva Holding SA.
Monday, January 28, 2013
Gyros AB Appoints Dr Henrik Björkman as CTO and VP Technical Affairs
Dr Henrik Björkman will lead the R&D and product supply teams.
Monday, January 21, 2013
Gyros AB Quality Management System Receives ISO 9001:2008 Certification
Certification reassures customers that they receive consistently high standard of products and services.
Tuesday, December 18, 2012
Gyros and GE Healthcare Life Sciences Expand Asian Distribution Relationship
Gyros AB announces that GE Healthcare Life Sciences has become sole distributor for the company’s nanoliter-scale immunoassay platform in China, Taiwan and Hong Kong.
Friday, August 26, 2011
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Experimental Therapy For Brain Cancer Could Prevent Drug Resistance
Information from penny-sized microfluidic chips allowed researchers to anticipate resistance to cancer treatment.
3D Printing of Lego Fluidics
Study shows how 3D printing can open up microfluidic technology to a wider audience.
New Method to Preserve Device to Monitor HIV Treatment
Inspired by pregnancy tests, scientists have developed a method to store microfluidic devices for months without refrigeration, giving developing countries an inexpensive and reliable way to treat patients.
Migration Creates Cancer Cell Vulnerabilities
Scientists found that migration can damage cancer cells’ nuclei and DNA, requiring repairs for their survival. The results may open new avenues for targeting metastatic cancer.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!